AW
VIVO

ACG Wealth’s Meridian Bioscience Inc VIVO Stock Holding History

ACG Wealth’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,120
Closed -$308K – 1090
2022
Q2 		$308K Sell
10,120
-520
-5% -$14.1K 0.06% 208
2022
Q1 		$276K Hold
10,640
– – 0.05% 231
2021
Q4 		$217K Hold
10,640
– – 0.03% 301
2021
Q3 		$205K Buy
10,640
+750
+8% +$14.9K 0.03% 291
2021
Q2 		$219K Buy
9,890
+1,850
+23% +$39.2K 0.03% 290
2021
Q1 		$211K Buy
+8,040
New +$191K 0.03% 294

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACG Wealth's VIVO Position: Q3 2022 in Review

ACG Wealth sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 10,120 shares — an estimated $308K sold.

ACG Wealth first reported a position in VIVO in Q1 2021 and held it in 6 quarters. The position peaked at $308K in Q2 2022. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • ACG Wealth reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
  • ACG Wealth sold 10,120 Meridian Bioscience Inc shares in Q3 2022, an estimated $308K.
  • ACG Wealth first reported a position in Meridian Bioscience Inc in Q1 2021 and held it in 6 quarters.
  • ACG Wealth's Meridian Bioscience Inc position peaked at $308K in Q2 2022.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on ACG Wealth's 13F filing for Q3 2022, filed 3 Nov 2022.